Zepbound Outperforms Wegovy in Weight Loss Trial

By Rene Pretorius

December 6, 2024

The news release from Eli Lilly and Company, titled “Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial, highlights the critical comparison of Zepbound vs Wegovy in treating obesity. Zepbound has shown superior efficacy, making it a compelling option for managing weight in adults.

The SURMOUNT-5 trial involved adults living with obesity or overweight with at least one weight-related medical condition but without diabetes. Zepbound outperformed Wegovy on both the primary endpoint and five key secondary endpoints at 72 weeks. The trial demonstrated that Zepbound was superior to Wegovy in terms of weight loss. Participants using Zepbound achieved an average weight loss of 20.2%, compared to 13.7% for those taking Wegovy. In terms of absolute weight loss, those on Zepbound lost 50.3 lbs (22.8 kg), while participants on Wegovy lost 33.1 lbs (15.0 kg). A key secondary endpoint showed that 31.6% of people taking Zepbound achieved at least 25% body weight loss, compared to just 16.1% of those taking Wegovy.

Mechanism of Action – Zepbound vs Wegovy

Tirzepatide, the active ingredient in Zepbound, is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. In contrast, semaglutide is a mono GLP-1 receptor agonist.

Safety Profile

The overall safety profile of Zepbound in the SURMOUNT-5 trial was similar to previous studies. The most commonly reported adverse events were gastrointestinal-related and generally mild to moderate in severity.

Regulatory and Market Status

Tirzepatide is commercialized as Zepbound for adults with obesity or overweight and weight-related medical problems in some global markets outside the U.S. It received U.S. FDA approval on November 8, 2023, for this indication and is also marketed as Mounjaro for adults with type 2 diabetes.

Ongoing and Future Zepbound Studies

Ongoing studies of tirzepatide focus on its effects in four disease areas. These areas are chronic kidney disease (CKD), morbidity/mortality in obesity (MMO), moderate-to-severe obstructive sleep apnea (OSA), and heart failure with preserved ejection fraction (HFpEF). The data reinforces the efficacy and safety of Zepbound vs Wegovy in managing obesity. Zepbound is a significant treatment option for adults with obesity or those who are overweight and facing related medical challenges.

Reference url

Recent Posts

drug price comparison
 

Global Drug Price Gaps Demand Better Drug Pricing Analysis

💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.

But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?

Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.

#SyenzaNews #healthcare #pricing

NICE HealthTech Reforms
            

NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global Healthcare Systems

🌐 Are you ready to witness a paradigm shift in digital health technology?

The National Institute for Health and Care Excellence (NICE) has announced transformative reforms aimed at accelerating the adoption of digital health innovations within the NHS. By focusing on cost-effectiveness rather than mere cost savings, these changes promise to streamline regulatory processes and enhance evaluations aligned with healthcare priorities.

Dive into this insightful article to explore how NICE’s reforms could reshape the future of healthcare systems globally!

#SyenzaNews #DigitalHealth #HealthEconomics #Innovation

BioNTech BMS collaboration
   

BioNTech BMS Collaboration: Pioneering Advances in Solid Tumor Treatment with BNT327

🚀 What could a groundbreaking partnership between BioNTech and Bristol-Myers Squibb mean for the future of solid tumor therapy?

Their collaboration on BNT327 is set to revolutionize immuno-oncology with promising early-phase trial results and a strategic investment of over $1.5 billion. This innovative bispecific antibody targets both PD-L1 and VEGF-A, indicating potential for enhanced patient outcomes in challenging cancers like small cell lung cancer and triple-negative breast cancer.

Curious about how this partnership could reshape cancer treatments? Dive into the full analysis!

#SyenzaNews #oncology #drugdevelopment #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.